Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CAM Research Should Test For Adverse Interactions – Toxicologist

This article was originally published in The Tan Sheet

Executive Summary

Future research on complementary and alternative medicine should include clinical testing on interactions between dietary supplements and conventional medications, according to one toxicology expert

You may also be interested in...

NCCAM turns five

National Center for Complementary & Alternative Medicine celebrates its fifth anniversary by announcing the launch of its second five-year strategic plan, NIH center says during recent advisory council meeting. Draft of the plan will be released in the fall. NCCAM director Stephen Straus, MD, cites the center's research portfolio containing "over 300 projects" and including the "largest ever placebo-controlled clinical trials of popular dietary supplements like glucosamine for degenerative arthritis and ginkgo biloba for dementia" among NCCAM's noteworthy accomplishments. Straus also notes that "most importantly, a body of data is emerging from NCCAM's investments in research that is informing public policy and helping guide practices"...

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts